TICKERNOMICS Sign up
Last Update: 2024-03-28 02:12:39
Nurix Therapeutics Inc. ( NRIX ) https://www.nurixtx.com
13.02USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
NRIX
49.66%
SPY
32.74%
-56.37%
NRIX
SPY
92.93%
NRIX
0.00%
SPY
224.41%
NRIX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
653.80
467.87
0.67
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-4.81
9.53
3.26
-33.70
0.00
-3.19
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-216.67
100.00
-198.34
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-168.42
-52.07
0.00
Other Earnings and Cash Flow Stats:
Nurix Therapeutics Inc. ( NRIX ) Net Income TTM ($MM) is -147.93
Nurix Therapeutics Inc. ( NRIX ) Operating Income TTM ($MM) is -160.05
Nurix Therapeutics Inc. ( NRIX ) Owners' Earnings Annual ($MM) is -141.00
Nurix Therapeutics Inc. ( NRIX ) Current Price to Owners' Earnings ratio is -4.50
Nurix Therapeutics Inc. ( NRIX ) EBITDA TTM ($MM) is -146.51
Nurix Therapeutics Inc. ( NRIX ) EBITDA Margin is -198.34%
Capital Allocation:
Nurix Therapeutics Inc. ( NRIX ) has paid 0.00 dividends per share and bought back 5.309686 million shares in the past 12 months
Nurix Therapeutics Inc. ( NRIX ) has increased its debt by 19.952 million USD in the last 12 months
Capital Structure:
Nurix Therapeutics Inc. ( NRIX ) Interest-bearing Debt ($MM) as of last quarter is 30
Nurix Therapeutics Inc. ( NRIX ) Annual Working Capital Investments ($MM) are 12
Nurix Therapeutics Inc. ( NRIX ) Book Value ($MM) as of last quarter is 200
Nurix Therapeutics Inc. ( NRIX ) Debt/Capital as of last quarter is 15%
Other Balance Sheet Stats:
Nurix Therapeutics Inc. ( NRIX ) has 54 million in cash on hand as of last quarter
Nurix Therapeutics Inc. ( NRIX ) has 86 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Nurix Therapeutics Inc. ( NRIX ) has 48 common shares outstanding as of last quarter
Nurix Therapeutics Inc. ( NRIX ) has 0 million USD of preferred stock value
Academic Scores:
Nurix Therapeutics Inc. ( NRIX ) Altman Z-Score is -0.19 as of last quarter
Nurix Therapeutics Inc. ( NRIX ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Nurix Therapeutics Inc. ( NRIX ) largest shareholder is Charles Schwab Investment Management Inc owning 568576 shares at 7.40 ($MM) value
Houte Hans Van(an insider) Sold 6812 shares of Nurix Therapeutics Inc. ( NRIX ) for the amount of $68256.24 on 2024-02-16
2.69% of Nurix Therapeutics Inc. ( NRIX ) is held by insiders, and 96.89% is held by institutions
Nurix Therapeutics Inc. ( NRIX ) went public on 2020-07-24
Other Nurix Therapeutics Inc. ( NRIX ) financial metrics:
FCF:-174.37
Unlevered Free Cash Flow:-110.55
EPS:-3.04
Operating Margin:-216.67
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-73.78
Beta:0.00
Buffet's Owners Earnings:-141.00
Price to Owner's Earnings:-4.50
About Nurix Therapeutics Inc. ( NRIX ) :
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.